Carl Zeiss Meditec AG (MEX:AFXN) Moat Score: 7/10 (As of Jun. 24, 2026)


MEX:AFXN Carl Zeiss Meditec AG MEX:AFXN
68 GF Score
Price MXN3,258.20
GF Value MXN8,900.18
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Moat Score?

Carl Zeiss Meditec AG MEX:AFXN 68 Moat Score is 7 as of Jun. 24, 2026. GuruFocus rates MEX:AFXN with a GF Score™ of 68/100 and a GF Value™ of MXN8,900.18. The stock has 4 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 98.94% on this metric.

Carl Zeiss Meditec AG has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Carl Zeiss Meditec AG has Wide Moat: Carl Zeiss Meditec AG possesses a wide moat due to its valuable intellectual property, strong brand, and significant customer switching costs in the medical technology sector. Its consistent innovation and R&D capabilities further solidify its durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Carl Zeiss Meditec AG might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Carl Zeiss Meditec AG  (MEX:AFXN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Carl Zeiss Meditec AG Moat Score Related Terms

MEX:AFXN vs ISRG, BDX, MDLN: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Moat Score distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Moat Score falls into.


MEX:AFXN
68GF Score
Carl Zeiss Meditec AG MEX:AFXN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Carl Zeiss Meditec AG (MEX:AFXN) has a Moat Score of 7 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #9 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Carl Zeiss Meditec AG's Moat Score too high?
Carl Zeiss Meditec AG's current Moat Score is 7. Based on the distribution chart, Carl Zeiss Meditec AG ranks #9 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Moat Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #9 out of 846 companies for Moat Score. This places Carl Zeiss Meditec AG in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Carl Zeiss Meditec AG's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (MEX:AFXN) has a current Moat Score of 7. The stock's GF Value™ is MXN8,900.18, compared to a current price of MXN3,258.20 — trading 63.4% below its estimated fair value. The current Moat Score is 7. Carl Zeiss Meditec AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Carl Zeiss Meditec AG (MEX:AFXN), the current Moat Score is 7 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (MEX:AFXN) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of MXN3,258.20 is trading 63.4% below its estimated GF Value™ of MXN8,900.18.

Key valuation signals for MEX:AFXN:

  • Moat Score: 7
  • GF Value™: MXN8,900.18 vs. price of MXN3,258.20 (63.4% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:AFXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score

Get the complete analysis for MEX:AFXN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,258.20
Price
MXN8,900.18
GF Value